Trilaciclib plus docetaxel for advanced lung cancer (second-line+)
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new drug combination (trilaciclib plus docetaxel) for people with advanced lung cancer (NSCLC) whose cancer has progressed after at least one prior treatment. The goal is to see if adding trilaciclib helps the chemotherapy work better with fewer side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have advanced (stage IV) non-small cell lung cancer (NSCLC) that has gotten worse after at least one prior treatment. If you have a targetable gene change (like EGFR, BRAF, etc.), you must have had targeted therapy first, then chemo. If you don't have those gene changes, you must have had chemo plus immunotherapy.
- You have at least one tumor that can be measured on a scan.
- Your blood counts and organ function (kidney, liver) are within a healthy range, and you have a good activity level (ECOG 0-2).
- You have never been treated with docetaxel before.
- You are not pregnant (if female) and agree to use reliable birth control.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether adding trilaciclib to a new chemotherapy (sacituzumab tirumotecan) can help people with EGFR-mutant lung cancer that keeps growing after certain targeted treatments. The goal is to see if it slows the cancer and reduces side effects.
This trial tests if trilaciclib can protect your bone marrow during chemotherapy for advanced non-small cell lung cancer. The goal is to reduce side effects like low blood counts, which can cause fatigue, infections, or bleeding.
This trial tests a new drug (RC148) plus chemotherapy against another drug (Tislelizumab) plus chemotherapy for people with a type of lung cancer called squamous non-small cell lung cancer that has spread or can't be removed. It's for those who haven't had treatment for advanced disease yet.
This study tests a new combination of drugs (HS-20093 plus adebrelimab) against a standard chemotherapy (docetaxel) for people with advanced or metastatic non-squamous non-small cell lung cancer who have already had treatment. The goal is to see if the new combination is more effective and safer than the standard chemo.
This Phase 2 study tests the combination of trilaciclib and lurbinectidin in adults whose cancer has already been treated, including with certain standard medicines. It aims to see if this combination can shrink tumors or slow cancer growth.
This trial tests a combination of two drugs, trilaciclib and immunotherapy, for people with head and neck squamous cell carcinoma that has spread or come back and can't be treated with surgery or radiation. The goal is to see if this combination helps control the cancer.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.